Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

QTORIN™ (rapamycin) is positioned as a potential first FDA-approved therapy for microcystic lymphatic malformations, targeting an estimated 30,000+ pediatric and adult patients in the U.S. The claim implies a potential new standard of care, which is a meaningful positive development for the clinical/commercial outlook of the program.